BCL2L1 and breast cancer: Finally, by knocking down Bcl-xL in a Bcl-xL-dependent cell model, we examined whether also endogenous Bcl-xL could inhibit IP3Rs. We used a breast cancer model, the mammary gland adenocarcinoma cell line MDA-MB-231, in which Bcl-xL is important for survival [41] and migration [42].